Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-2: Neoadjuvant FOLFIRINOX versus gemcitabine-based chemoradiotherapy plus adjuvant gemcitabine in resectable or borderline resectable pancreatic cancer
NL-OMON60988Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan, fluorouracil, oxaliplatin, folinic acid and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Erasmus MC. Primary endpoints: Overall survival and Quality of life. Started Oct 2024; status: completed.
02
Drugs
irinotecanfluorouraciloxaliplatinfolinic acidgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON60988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60988.